The data that emerged from this study thus validate the hypothesis that DC-SCRIPT is associated with good prognosis in early disease and support the idea that DC-SCRIPT acts as a tumor suppressor in breast cancer progression [7]. Here, ZNF366 is linked to breast carcinoma.